Description

▪ Introduction

Aromaxen 1 contains pharmaceutical-grade Anastrozol, a non-steroidal aromatase inhibitor widely utilized in laboratory research involving estrogen suppression and hormonal regulation pathways. Manufactured by Novotex Pharma, this compound is supplied in tablet form to support controlled dosing in in-vitro and pharmacodynamic studies. Its high specificity for the aromatase enzyme makes it a valuable tool in estrogen modulation experiments and endocrine-related research.

▪ Product Details

• Active Ingredient: Anastrozol

• Dosage Strength: 1 mg per tablet

• Form: Oral tablets

• Brand: Novotex Pharma

• Package Size: 60 tablets (boxed, blister-packed)

• Intended Use: Laboratory and analytical use

▪ Pharmacokinetics

Anastrozol is rapidly absorbed via the gastrointestinal tract with peak plasma concentrations typically observed within 2 hours under simulated oral conditions. It exhibits a terminal half-life of approximately 40–50 hours and is metabolized primarily in the liver via N-dealkylation, hydroxylation, and glucuronidation pathways. The compound demonstrates a strong inhibitory effect on the aromatase enzyme, significantly reducing estradiol synthesis in estrogen-sensitive models.

▪ Usage Recommendations

In lab-based simulations, typical dosing models involve 0.5–1 mg per day, depending on the research objective. Tablets should be handled in a clean, controlled environment, and stored in their original blister packaging to maintain integrity. Avoid direct exposure to light and moisture.

▪ Disclaimer

This product is intended strictly for laboratory research and analytical use. Not approved for human use or medical treatment. Not suitable for anyone under 18, pregnant or breastfeeding women, or individuals with medical conditions. Must be handled in accordance with local regulatory guidelines and laboratory safety procedures.